Haloperidol versus chlorpromazine for treatment of schizophrenia

Leucht, Claudia; Kitzmantel, Maria; Chua, Lynette J.; Kane, John M.; Leucht, Stefan

doi:10.1093/schbul/sbn087

Cited by 10 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of 13 comparative trials of haloperidol versus chlorpromazine for schizophrenia is used as a worked example of comparing the selected methods. 19…”

Section: Besides the Well-discussed Frequentist Methods A Variety Ofmentioning

confidence: 99%

“…A meta-analysis of 13 comparative trials compared two drugs, haloperidol and chlorpromazine, which are commonly used to treat schizophrenia. 19 Patients leaving studies because of adverse events were recorded as outcomes. In this meta-analysis, 8 studies (62%) contained no events in any treatment arm, and events only occurred in one treatment arm in the other 5 (38%) studies.…”

Section: Case Studymentioning

confidence: 99%

See 1 more Smart Citation

Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews

et al. 2019

View full text Add to dashboard Cite

“…A meta-analysis of 13 comparative trials of haloperidol versus chlorpromazine for schizophrenia is used as a worked example of comparing the selected methods. 19…”

Section: Besides the Well-discussed Frequentist Methods A Variety Ofmentioning

confidence: 99%

Section: Case Studymentioning

confidence: 99%

Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews

et al. 2019

View full text Add to dashboard Cite

“…Haloperidol ( 2 ) is a well-known typical antipsychotic drug that belongs to this chemical class [45, 46]. Other drugs, such as bromperidol ( 18 ) [47, 48], trifluperidol ( 19 ) [49], lenperone ( 20 ) [50], benperidol ( 21 ) [51, 52], droperidol ( 22 ) [53], pipamperone ( 23 ) [54, 55] and spiperone ( 24 ) [56] are also from this family (Fig.…”

Section: Development Of Antipsychotics For the Treatment Of Schizophrmentioning

confidence: 99%

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Snyder²,

Vanover³

2016

CTMC

212

141

View full text Add to dashboard Cite

Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approximately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demonstrate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the unintentional engagement of multiple pharmacological targets or even the excessive engagement of intended pharmacological targets can lead to undesired consequences and poor tolerability. In this article, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia. Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metabolism and safety, pharmacological properties, preclinical data in animal models, clinical outcomes and associated side effects.

show abstract

“…The first, and preferred, strategy is the development of APs without risk of TD. The FGAs provided evidence supporting a central role for D 2 occupancy in antipsychotic efficacy; in addition, higher potency D 2 blocking agents (e.g., haloperidol) were not more clinically effective but were associated with a greater liability for EPS [47][48][49]. Clozapine's relatively low affinity for the D 2 receptor raised the possibility that AP efficacy may be possible through mechanisms beyond D 2 antagonism [50], and although numerous attempts have been made, as of yet none have been successful.…”

Section: Current Research Goalsmentioning

confidence: 98%

Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Lockwood

Remington

2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

Haloperidol versus chlorpromazine for treatment of schizophrenia

Cited by 10 publications

References 5 publications

Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews

Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Contact Info

Product

Resources

About